Amivantamab Shows Unprecedented Response Rates in Treatment-Resistant Head and Neck Cancer
核心洞察
Amivantamab injection achieved tumor shrinkage in 42% of patients with treatment-resistant head and neck cancer, with 15 patients experiencing complete tumor disappearance.
The bispecific monoclonal antibody targets EGFR (搜索) and MET pathways while activating immune responses, offering a convenient subcutaneous injection alternative to intravenous treatments.
Patients lived for a median of 12.5 months after starting treatment despite having cancers with very poor outcomes once standard treatments fail.
Doctors are celebrating "unprecedentedly strong responses" to a cancer injection that eradicated entire tumors in treatment-resistant cases during a breakthrough clinical trial. The drug amivantamab, developed by Johnson & Johnson, demonstrated remarkable efficacy in patients with recurrent and metastatic head and neck cancer whose disease had stopped responding to standard treatments.
Trial Results Show Dramatic Tumor Response
The phase of the OrigAMI-4 trial examined 102 patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) from 55 hospitals across 11 countries. These patients had exhausted conventional treatment options, with their cancers continuing to grow despite immunotherapy and platinum-based chemotherapy.
Tumors shrank in 43 participants - representing 42% of the study population. Of these responders, 15 patients experienced complete tumor disappearance while 28 saw significant tumor shrinkage. The responses began within approximately six weeks of treatment initiation.
"These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy," said Professor Kevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research (ICR), London, and consultant oncologist at The Royal Marsden NHS Foundation Trust. "This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."
Survival Benefits in Advanced Disease
Despite treating patients with cancers known for "very poor outcomes" once standard treatments fail, those receiving amivantamab lived for a median of 12.5 months after starting treatment. Patients experienced a median of slightly more than six-and-a-half months before cancer progression occurred.
The drug's impact extended beyond survival statistics to meaningful quality of life improvements. Carl Walsh, 56, from Birmingham, was diagnosed with tongue cancer in May 2024 and joined the study at The Royal Marsden in July 2025 after both chemotherapy and immunotherapy proved unsuccessful.
"I now feel able to live a normal life. Before starting the trial, I struggled to speak properly and found eating difficult because of the swelling and pain," Walsh said during his 17th treatment cycle. "Since beginning treatment, the swelling has reduced significantly, and my pain levels have improved considerably. I'm also no longer experiencing the same life-impacting side effects that I had during chemotherapy."
Novel Mechanism of Action
Amivantamab functions as a bispecific monoclonal antibody with a triple mechanism of action. The drug simultaneously blocks two critical cancer growth signals: EGFR (搜索) (Epidermal Growth Factor Receptor), a protein that promotes tumor growth, and MET, a separate pathway frequently exploited by cancer cells to escape treatment. Additionally, the drug activates the immune system to attack tumors.
The treatment is administered as a subcutaneous injection every three weeks, offering significant advantages over traditional intravenous cancer therapies. This delivery method is faster, more convenient for patients, and "significantly easier" to deliver in outpatient clinics, according to the ICR.
Safety Profile and Treatment Tolerability
Side effects from amivantamab were characterized as mild to moderate, with fewer than 10 patients discontinuing treatment due to adverse events. This favorable safety profile represents a marked improvement over the "life-impacting side effects" many patients experienced with previous chemotherapy regimens.
Addressing an Unmet Medical Need
Head and neck cancer ranks as the sixth most common cancer worldwide, affecting approximately 12,800 people annually in the UK. The study specifically excluded patients with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma, focusing instead on the more challenging non-HPV related cases that typically demonstrate poorer responses to standard therapy.
"Head and neck cancers that are not caused by HPV are usually harder to treat and have poorer responses to standard therapy," the ICR noted, emphasizing that "making progress in this group [is] particularly important."
Broader Clinical Applications
Amivantamab has already received approval for multiple subtypes of lung cancer across various treatment lines. The drug is currently being evaluated in approximately 60 clinical trials, primarily focusing on lung cancer applications but also investigating its potential in colorectal, brain, and gastric cancers.
Professor Kristian Helin, chief executive of the ICR, emphasized the study's significance: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumor response and encouraging survival outcomes in such a challenging to treat group represents a significant step forward."
Harrington concluded that the treatment "has the potential to benefit many thousands of patients each year." The complete study results will be presented at the American Society of Clinical Oncology annual meeting.